Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Holdings Lifted by Finepoint Capital LP

Finepoint Capital LP grew its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 21.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 161,935 shares of the biotechnology company’s stock after acquiring an additional 28,400 shares during the quarter. Sarepta Therapeutics comprises 1.2% of Finepoint Capital LP’s portfolio, making the stock its 9th biggest position. Finepoint Capital LP’s holdings in Sarepta Therapeutics were worth $19,690,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Manchester Capital Management LLC raised its stake in shares of Sarepta Therapeutics by 86.6% in the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 110 shares during the period. MassMutual Private Wealth & Trust FSB raised its position in Sarepta Therapeutics by 169.6% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 156 shares during the period. Sunbelt Securities Inc. raised its position in Sarepta Therapeutics by 446.2% in the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 232 shares during the period. Newbridge Financial Services Group Inc. acquired a new position in shares of Sarepta Therapeutics during the fourth quarter worth about $36,000. Finally, Steward Partners Investment Advisory LLC boosted its position in shares of Sarepta Therapeutics by 164.4% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company’s stock worth $38,000 after buying an additional 194 shares during the period. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Sarepta Therapeutics Stock Down 7.1 %

SRPT stock opened at $54.43 on Friday. The stock has a market cap of $5.28 billion, a PE ratio of 43.54 and a beta of 0.79. The firm’s 50-day simple moving average is $96.95 and its 200 day simple moving average is $113.70. Sarepta Therapeutics, Inc. has a fifty-two week low of $54.26 and a fifty-two week high of $173.25. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93.

Analyst Ratings Changes

Several equities research analysts recently commented on SRPT shares. Needham & Company LLC dropped their target price on Sarepta Therapeutics from $202.00 to $183.00 and set a “buy” rating on the stock in a report on Thursday. Cantor Fitzgerald restated an “overweight” rating and issued a $163.00 target price on shares of Sarepta Therapeutics in a research note on Tuesday, March 18th. Royal Bank of Canada downgraded shares of Sarepta Therapeutics from an “outperform” rating to a “sector perform” rating and dropped their price target for the stock from $161.00 to $87.00 in a research note on Monday, March 31st. Scotiabank lowered their target price on Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating for the company in a research note on Thursday, March 20th. Finally, Deutsche Bank Aktiengesellschaft dropped their target price on Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating on the stock in a research report on Wednesday, March 19th. Six analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Sarepta Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $163.18.

Insider Buying and Selling at Sarepta Therapeutics

In other news, Director Claude Nicaise sold 2,491 shares of the stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the sale, the director now owns 27,812 shares in the company, valued at $2,771,187.68. This represents a 8.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 7.70% of the stock is currently owned by corporate insiders.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.